228 related articles for article (PubMed ID: 12670470)
21. Historical overview of hairy cell leukemia.
Andritsos LA; Grever MR
Best Pract Res Clin Haematol; 2015 Dec; 28(4):166-74. PubMed ID: 26614894
[TBL] [Abstract][Full Text] [Related]
22. Multiply relapsing hairy cell leukemia responsive to repeated courses of rituximab: a case report.
Buckstein R; Patel H; Chesney A; Reis M; Imrie K
Hematology; 2006 Aug; 11(4):267-70. PubMed ID: 17178666
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases.
Hoffman MA
Med Oncol; 2011 Dec; 28(4):1537-41. PubMed ID: 20509009
[TBL] [Abstract][Full Text] [Related]
24. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Arons E; Sorbara L; Raffeld M; Stetler-Stevenson M; Steinberg SM; Liewehr DJ; Pastan I; Kreitman RJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1100-10. PubMed ID: 16311729
[TBL] [Abstract][Full Text] [Related]
25. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
26. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
27. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
28. Cladribine in the treatment of hairy-cell leukaemia.
Goodman GR; Beutler E; Saven A
Best Pract Res Clin Haematol; 2003 Mar; 16(1):101-16. PubMed ID: 12670469
[TBL] [Abstract][Full Text] [Related]
29. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
30. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Huynh E; Sigal D; Saven A
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():12-7. PubMed ID: 19814692
[TBL] [Abstract][Full Text] [Related]
31. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.
Blasińska-Morawiec M; Robak T; Krykowski E; Hellmann A; Urbańska-Ryś H
Leuk Lymphoma; 1997 Apr; 25(3-4):381-5. PubMed ID: 9168448
[TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
Nieva J; Bethel K; Saven A
Blood; 2003 Aug; 102(3):810-3. PubMed ID: 12663446
[TBL] [Abstract][Full Text] [Related]
33. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
34. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
35. Rituximab in the treatment of the variant of hairy cell leukaemia: a case report.
Hadzi-Pecova L; Stojanovik A; Petrusevska G; Panovska I
Prilozi; 2008 Dec; 29(2):355-60. PubMed ID: 19259059
[TBL] [Abstract][Full Text] [Related]
36. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
37. Advances in the treatment of hairy-cell leukaemia.
Mey U; Strehl J; Gorschlüter M; Ziske C; Glasmacher A; Pralle H; Schmidt-Wolf I
Lancet Oncol; 2003 Feb; 4(2):86-94. PubMed ID: 12573350
[TBL] [Abstract][Full Text] [Related]
38. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
[TBL] [Abstract][Full Text] [Related]
39. Toxin-labeled monoclonal antibodies.
Kreitman RJ
Curr Pharm Biotechnol; 2001 Dec; 2(4):313-25. PubMed ID: 11762413
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
Dehghani M; Kashkooe A; Namdari N; Majidi R; Karimi M; Haghighat S; Rezvani A; Safari N
Expert Rev Hematol; 2023 Apr; 16(4):289-295. PubMed ID: 36709461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
